ZENSUN ENT (00185) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 2.624 billion, representing a year-on-year increase of 1,326.78%. The loss attributable to shareholders was RMB 502 million, narrowing by 68.56% compared to the same period last year. Basic loss per share was 26.2 cents.